Patent · US Active

Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen

US11324819B2 · kind B2 · utility

0Cited by

1References

16Claims

0Family size

Assignees

University of Washington · US
ABACUS BIOSCIENCE, INC. · US

Inventors

Edward Clark · Seattle, US
Deborah Fuller · Middleton, US
Che-Leung Law · Bothell, US
Amanda MAK · Seattle, US

Key dates

Filing date	Nov 22, 2016
Grant date	May 10, 2022
Priority date	—
Expiry date	Sep 29, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2730/10171
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.